The Future of Radioligand Therapy: α, β, or Both?-Reference-Cited by-同舟云学术

The Future of Radioligand Therapy: α, β, or Both?

Published:2017-04-13 Issue:7 Volume:58 Page:1017-1018
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Haberkorn Uwe,Giesel Frederik,Morgenstern Alfred,Kratochwil Clemens

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Reference12 articles.

1. The promise of targeted-particle therapy;Mulford;J Nucl Med.,2005

2. 213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience

3. 225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer

4. Kratochwil C Bruchertseifer F Hendrik R . Targeted alpha therapy of mCRPC with 225actinium-PSMA-617: dosimetry estimate and empirical dose finding. J Nucl Med. April 13, 2017 [Epub ahead of print].

5. Improved efficacy of α-particle-targeted radiation therapy

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Radionuclide Therapy in Glioblastoma;ACS Applied Materials & Interfaces;2024-07-23

2. Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer;Nature Reviews Urology;2024-07-08

3. Role of Lutetium Radioligand Therapy in Prostate Cancer;Cancers;2024-07-01

4. 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice;Current Oncology;2024-03-07

5. The prostate-specific membrane antigen holds potential as a vascular target for endogenous radiotherapy with [177Lu]Lu-PSMA-I&T for triple-negative breast cancer;Breast Cancer Research;2024-02-20